Trial · NCT03100864
Adverse events25
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 25
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Conjunctival haemorrhage | Eye disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Eye inflammation | Eye disorders | Spesolimab 1200 mg Intravenous (i.v.) | 2 | 8 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Colitis ulcerative | Gastrointestinal disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Dyspepsia | Gastrointestinal disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Fatigue | General disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Gastrointestinal infection | Infections and infestations | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Nasopharyngitis | Infections and infestations | Spesolimab 1200 mg Intravenous (i.v.) | 4 | 8 | |
| other | Tonsillitis | Infections and infestations | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Amylase increased | Investigations | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Lipase increased | Investigations | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Musculoskeletal pain | Musculoskeletal and connective tissue disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Headache | Nervous system disorders | Spesolimab 1200 mg Intravenous (i.v.) | 2 | 8 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Spesolimab 1200 mg Intravenous (i.v.) | 1 | 8 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03100864/events